Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer

Michael Morris • 22 May 2020
ASCO 2020
Prostate Cancer Atezolizumab Radium-223

Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses results from a phase Ib study evaluating the safety and tolerability of atezolizumab with radium-223 in patients with metastatic castrate-resistance prostate cancer who have progressed after treatment with an androgen pathway inhibitor (NCT02814669). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Michael Morris

7:42
CONDOR: 18F-DCFPyL PET/CT imaging in suspected reccuring prostate cancer
Michael Morris • 22 May 2020
1:42
Role of Medical Oncologists in prostate cancer management
Michael Morris • 15 Feb 2019
2:52
DORA trial: radium-223 plus docetaxel for mCRPC
Michael Morris • 15 Feb 2019
1:01
A promising treatment for prostate cancer
Michael Morris • 15 Feb 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals